GlassScriptPhysician profile
Kruti Patel
NPI 1700273760
$18,064.66
in general payments reported to CMS, 2019-2025
37 companies · $8,823 in 2025
The $8,823 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.95 · 2022: $2,506 · 2023: $478 · 2024: $6,212 · 2025: $8,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,364 · Consulting Fee: $3,133 · Food and Beverage: $2,922 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,364.00 |
| Consulting Fee | $3,132.50 |
| Food and Beverage | $2,921.91 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14,117.70 | 2022-2025 | |
| Janssen Biotech, INC. | $1,377.04 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $525.59 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $205.36 | 2022-2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $191.79 | 2023-2025 | |
| Astellas Pharma US INC | $177.77 | 2024-2025 | Xospata, Vyloy, Cresemba |
| Adaptive Biotechnologies Corporation | $151.50 | 2023-2024 | Clonoseq |
| Janssen Scientific Affairs, LLC | $118.83 | 2025 | Talvey, Tecvayli, Darzalex |
| Legend Biotech USA INC. | $109.58 | 2024-2025 | Carvykti |
| Daiichi Sankyo INC. | $107.79 | 2023-2025 | Vanflyta |
| Genmab U.S., INC. | $105.06 | 2024-2025 | Epkinly |
| Pfizer INC. | $95.74 | 2025 | |
| Pharmaessentia USA Corporation | $69.86 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $68.70 | 2024-2025 | Yescarta |
| Incyte Corporation | $68.44 | 2025 | Jakafi, Niktimvo, Niktimvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $62.87 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $61.96 | 2023-2025 | Ojjaara |
| Taiho Oncology, INC. | $59.99 | 2025 | |
| Amgen INC. | $45.19 | 2022-2023 | Blincyto, Kyprolis |
| Sanofi-Aventis U.S. LLC | $43.53 | 2025 | |
| Lilly USA, LLC | $36.43 | 2024-2025 | Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $35.09 | 2025 | Onivyde, Tazverik |
| Celgene Corporation | $30.43 | 2022-2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $24.73 | 2024 | |
| Merck Sharp & Dohme LLC | $23.48 | 2025 | Prevymis |
| Genentech USA, INC. | $22.53 | 2025 | Columvi |
| Morphosys, US INC. | $22.28 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $21.95 | 2025 | |
| Cti Biopharma Corp. | $21.70 | 2023 | Vonjo |
| Blueprint Medicines Corporation | $17.17 | 2021 | |
| Kyowa Kirin, INC. | $16.80 | 2023 | Poteligeo |
| Astrazeneca Pharmaceuticals LP | $15.94 | 2021 | |
| Seagen INC. | $11.84 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kruti Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.